U.S. companies dominated the investment landscape, capturing 70% of global spacetech funding in Q2, or roughly $2.2 billion.

Secondary marketplace for private securities EquityZen is out with a note on Q2 activity. The company stated that Circle's successful initial public offering ...

The space economy posted one of its hottest quarters since 2021 without a single SpaceX mega-round. Here's a recap of the top ...

Demand for Big Data services is increasing. Palantir, a leader in the field, should benefit. Here are the forecasts and price ...

After a couple years in a slump, initial public offerings have rebounded in 2025. Arnaud Blanchard, global co-head of equity capital markets at Morgan Stanley, joins us to discuss how IPOs from ...

Voyager Technologies is a buy, backed by space commercialization, NASA funding, and national security tailwinds. Learn more ...

Venture capital companies remained the most active space investors in recent months, contributing 77% of 2025 funding in the ...

Review Voyager Technologies Inc Class A (VOYG:XNYS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

The boards of directors of both Voyager and VERAXA unanimously approved the Business Combination. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. The ...

IPO/MergerXlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4 17.07.2025 / 07:00 CET/CESTThe filing demonstrates continued momentum ...

Review the current valuation for Voyager Technologies Inc Class A (VOYG:XNYS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

VY1706, an IV-delivered tau silencing gene therapy that has shown up to 73% knockdown of tau mRNA in non-human primates following a single IV dose and is advancing towards IND in 2026.